

Supplementary Table S1: Study Representativeness Table

Cancer type	Acute Myeloid Leukemia (AML)
Considerations related to:	
Cancer staging	An estimated 20,380 new cases of AML were expected in 2022, and the death rate was estimated to be over half of the new cases (11,310). The majority of deaths is likely an undercount of relapsed / refractory AML as some relapsed patients can have survival benefit after treatment. In fact, relapsed/ refractory AML patients are the ones who need innovative allogeneic Hematopoietic Cell Transplant (HCT) approaches to extend survival. ¹
Gender	Although AML is not appreciated to have a gender predilection, slightly more males 6440 will die from AML compared to women 4870 in 2023. ¹
Age	The average age of patients when they are first diagnosed with AML is about 68. ²
Race / Ethnicity	While non-hispanic whites have the highest incidence rate of AML in 2015-2019 of 14.9 per 100,000, American Indian and Alaskan Natives are not far behind with 12.6, Hispanics with 11.3 and Non-Hispanic blacks 10.9 per 100,000. However, non-Hispanic blacks have a higher death rate per 100,000 in 2016-2020 with 5.3 compared to Hispanics at 4.3 or Asian Pacific Islander at 3.4 and non-hispanic whites at 6.4 per 100,000 according to data from the American Cancer Society. ²
Other Considerations	Acute Leukemias and MDS/MPN continue to be the top 3 indications for allogeneic HCT in the US according to CIBMTR. ³
Overall representativeness of this study	In this study, 5 patients were Asian, 4 Black or African American, 1 Hispanic, and the other 15 were white. While these numbers are small, the patients in this trial do follow national HCT trends where in 2020 the majority of allogeneic HCTs patients were non-hispanic whites (69%), followed by Hispanics (15%), non-hispanic Blacks (9%) and Asians (4%). ³

¹Siegel et al., CA CANCER J CLIN 2023.

²ACS Cancer Statistics Center, <https://cancerstatisticscenter.cancer.org/cancer-site/Leukemia/5j5EUt8W>.

³Auletta JJ, Kou J, Chen M, Shaw BE. Current use and outcome of HCT: CIBMTR US summary slides, 2021.